Lantheus Files 8-K for Regulation FD Disclosure on Jan 26, 2024
Ticker: LNTH · Form: 8-K · Filed: Jan 26, 2024 · CIK: 1521036
| Field | Detail |
|---|---|
| Company | Lantheus Holdings, Inc. (LNTH) |
| Form Type | 8-K |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulation-fd, disclosure, corporate-governance
TL;DR
**Lantheus just filed an 8-K for Regulation FD, expect news soon!**
AI Summary
Lantheus Holdings, Inc. filed an 8-K on January 26, 2024, under Regulation FD Disclosure, indicating they are making a public announcement of material non-public information. This filing ensures that all investors receive important company updates simultaneously, preventing unfair trading advantages. For shareholders, this means any significant news, such as financial results or strategic developments, will be disclosed transparently, impacting their investment decisions.
Why It Matters
This filing signals that Lantheus is about to release important information, ensuring all investors get it at the same time, which is crucial for fair trading and informed decisions.
Risk Assessment
Risk Level: low — This 8-K is a procedural filing for Regulation FD disclosure, which generally indicates transparency rather than a specific risk event.
Analyst Insight
A smart investor would monitor news releases from Lantheus Holdings, Inc. closely following this Regulation FD disclosure, as it signals that material information is likely to be made public soon.
Key Players & Entities
- Lantheus Holdings, Inc. (company) — the registrant filing the 8-K
- January 26, 2024 (date) — date of earliest event reported and filing date
- Regulation FD Disclosure (other) — the item information disclosed in the 8-K
- 001-36569 (other) — Commission File Number for Lantheus Holdings, Inc.
- LNTH (other) — trading symbol for Lantheus Holdings, Inc. common stock
FAQ
What is the purpose of Lantheus Holdings, Inc.'s 8-K filing on January 26, 2024?
The purpose of the 8-K filing by Lantheus Holdings, Inc. on January 26, 2024, is for "Regulation FD Disclosure," as stated in the 'ITEM INFORMATION' section of the filing.
What is the trading symbol and exchange for Lantheus Holdings, Inc.'s common stock?
Lantheus Holdings, Inc.'s common stock trades under the symbol 'LNTH' on The Nasdaq Global Market, as indicated in the 'Securities registered pursuant to Section 12(b) of the Act' section.
What is the business address and phone number of Lantheus Holdings, Inc. as listed in the filing?
The business address for Lantheus Holdings, Inc. is 201 Burlington Road, South Building, Bedford, Massachusetts 01730, and their telephone number is (978) 671-8001, according to the filing.
What was the former name of Lantheus Holdings, Inc. and when did the name change occur?
The former name of Lantheus Holdings, Inc. was Lantheus MI Holdings, Inc., and the date of the name change was 20110517, as detailed in the 'FORMER COMPANY' section of the filing.
Is Lantheus Holdings, Inc. considered an emerging growth company according to this 8-K filing?
No, the filing indicates that Lantheus Holdings, Inc. is not an emerging growth company, as the checkbox for 'emerging growth company' is not marked.
Filing Stats: 712 words · 3 min read · ~2 pages · Grade level 12.6 · Accepted 2024-01-26 07:59:58
Key Financial Figures
- $0.01 — ich registered Common stock, par value $0.01 per share LNTH The Nasdaq Global Ma
Filing Documents
- d740568d8k.htm (8-K) — 23KB
- 0001193125-24-016143.txt ( ) — 142KB
- lnth-20240126.xsd (EX-101.SCH) — 3KB
- lnth-20240126_lab.xml (EX-101.LAB) — 18KB
- lnth-20240126_pre.xml (EX-101.PRE) — 11KB
- d740568d8k_htm.xml (XML) — 3KB
01
Item 7.01. Regulation FD. On January 26, 2024, Lantheus Holdings, Inc. (the "Company") confirmed that the Company and its subsidiary, Lantheus Medical Imaging, Inc., were sued by Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA, each a Novartis entity, for patent infringement in response to the Company's filing of Abbreviated New Drug Application ("ANDA") No. 217060 for Lutetium Lu 177 Dotatate (177Lu-PNT2003), a generic version of LUTATHERA (lutetium Lu 177 dotatate). LUTATHERA is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Based on the most recent update to the FDA's online paragraph IV database listings, the Company believes it is the "first applicant" to have filed a substantially complete ANDA for Lutetium Lu 177 Dotatate containing a Paragraph IV certification under the provisions of the Hatch-Waxman Act. As the "first applicant," the Company believes it is eligible for 180 days of generic marketing exclusivity in the U.S. The plaintiff has filed a lawsuit for patent infringement against the Company in the United States District Court for the District of Delaware. The information furnished pursuant to this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act. This Form 8-K contains "forward-looking statements" that are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements relating to the potential FDA approval of and potential generic marketing exclusivity relating to 177Lu-PNT2003 and statements regarding the Company's expectat
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LANTHEUS HOLDINGS, INC. By: /s/ Daniel M. Niedzwiecki Name: Daniel M. Niedzwiecki Title: Chief Administrative Officer and General Counsel Date: January 26, 2024